AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03039023 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phosphatidylcholine capsules
Description: 420 mg phosphatidylcholine capsules obtained from a commercial source.
Study NCT02616614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Onexton
Description: Topical gel for treating acne
Study NCT02616614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin/benzoyl peroxide gel
Description: Generic Clindamycin/benzoyl peroxide gel for treating acne
Study NCT02616614 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle gel used as a placebo
Study NCT03509636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: Fluzoparib capsule will be given twice daily orally
Study NCT04638959 — intervention group
Intervention type: OTHER
Intervention: collect gastric tissue and stool samples
Description: collect gastric tissue and stool samples
Study NCT04121403 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Biosimilar rituximab concentrate for solution for infusion
Study NCT04121403 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cladribine
Description: Mavenclad oral cladribine tablets
Study NCT00872664 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: carotenoids
Description: beta-carotene, lycopene, lutein
Study NCT04045951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myopia prediction algorithm
Description: Candidate predictors included age at examination, SER, and annual progression rate. Using these predictors, the algorithm will be used to predict SER at 3 years.
Study NCT01764126 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pneumococcal protein vaccine
Description: One dose of 50 µg of each of three proteins with adjuvant (aluminium hydroxide) IM
Study NCT01764126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal protein vaccine
Description: One dose of 50 µg of each of three proteins with adjuvant (aluminium hydroxide) IM
Study NCT01764126 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pneumococcal protein vaccine
Description: Three doses, 4 weeks apart, of 10 µg of each of three proteins with adjuvant (aluminium hydroxide) IM
Study NCT01764126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal protein vaccine
Description: Three doses, 4 weeks apart, of 10 µg of each of three proteins with adjuvant (aluminium hydroxide) IM
Study NCT01764126 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pneumococcal protein vaccine
Description: Three doses, 4 weeks apart, of 25 µg of each of three proteins with adjuvant (aluminium hydroxide) IM
Study NCT01764126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal protein vaccine
Description: Three doses, 4 weeks apart, of 25 µg of each of three proteins with adjuvant (aluminium hydroxide) IM
Study NCT01764126 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pneumococcal protein vaccine
Description: Three doses, 4 weeks apart, of 25 µg of each of three proteins without adjuvant IM
Study NCT01764126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal protein vaccine
Description: Three doses, 4 weeks apart, of 25 µg of each of three proteins without adjuvant IM
Study NCT01764126 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pneumococcal protein vaccine
Description: Three doses, 4 weeks apart, of 50 µg of each of three proteins with adjuvant (aluminium hydroxide) IM
Study NCT01764126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal protein vaccine
Description: Three doses, 4 weeks apart, of 50 µg of each of three proteins with adjuvant (aluminium hydroxide) IM
Study NCT01191541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNR:
Description: DNR：45mg/m2 d1-3
Study NCT01191541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DNR:
Description: DNR：45mg/m2 d1-3
Study NCT01191541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ara-c
Description: DNR+ARA-C：DNR：45mg/m2 d1-3;Ara-C :1g/m2 d1-3
Study NCT03267953 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Health CheckUp Online Stress Management Program
Description: Self-contained, web-based, stress management program developed by team of health care professionals, designed to encourage patients to learn evidence-based cognitive and behavioural strategies to effectively manage stress. Health risk appraisals include evidence-based recommendations to address risks. Stress management modules include education about the impact of stress, self-monitoring through a stress diary, and using four key strategies: physical activity, deep breathing and relaxation, problem-solving/addressing negative thoughts, and sleep hygiene. Through the modules, patients will learn new stress management strategies and have an opportunity to practice these, track their progress, and obtain feedback via the website. To facilitate self-monitoring of stress levels and tracking of strategies such as physical activity, tracking tools can be used on mobile devices.
Study NCT03267953 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lay telephone coaching
Description: The goal of telephone coaching will be to provide brief encouragement on how to use the modules; however, no formal therapy will be provided. Sessions will range between 10-15 minutes. Each coach session will follow the process outlined by the GROW model, which stands for Goal, Reality, Options/Obstacles, and Will/Way forward. The sessions will start with the coach and participant agreeing on the topics for discussion and desired outcomes (goal). Then, coaches will explore the use of the intervention over the previous week, guide participants through the modules, identify barriers to using these modules, offer advice to overcome these barriers, and provide positive reinforcement. The development of an action plan for the following week will conclude each session. The short Perceived Stress Scale will be used at the end of each session to monitor progress. A script will guide the lay coach through each call.
Study NCT03267953 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (telephone)
Description: Sessions will range from 30 to 45 minutes. The goal of MI is to strengthen patients' motivation and confidence for adopting the stress management strategies suggested. The MI practitioner's interventions are based on the four processes of MI: Engaging, Focusing, Evoking, and Planning.
Study NCT03934255 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constant Routine Protocol
Description: Constant routine protocols are used in circadian research to examine underlying circadian rhythms in the absence of light, activity, and meals
Study NCT01541579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cx601
Description: 120 million cells administered by intralesional injection.
Study NCT01541579 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: 24 mL saline solution by intralesional injection
Study NCT00564824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Caffeine 200 mg tablet
Study NCT00564824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo pills
Study NCT01364623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose testosterone nasal gel, single dose
Description: Low dose testosterone nasal gel, single dose
Study NCT01364623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medium dose testosterone nasal gel, single dose
Description: Medium dose testosterone nasal gel, single dose
Study NCT01364623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose testosterone nasal gel, single dose
Description: High dose testosterone nasal gel, single dose
Study NCT01364623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medium dose testosterone nasal gel, multiple dose
Description: Medium dose testosterone nasal gel, multiple dose
Study NCT04374409 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-flavanol cocoa powder
Description: Non-alkalized fat-reduced cocoa powder (Natural Acticoa)
Study NCT04374409 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low-flavanol cocoa powder
Description: Alkalized fat-reduced cocoa powder (10/12 DDP Royal Dutch)
Study NCT03021148 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Administration of questionnaire.
Study NCT03974334 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OWL-Hypertension 8 Wk Trial
Description: Our Whole Lives - Hypertension is an innovative online community and self-management program that provides access to stress reduction, mind-body techniques, nutrition, exercise, and peer support. OWL-H provides educational materials including videos of clinician-led talks (stress reactivity, nutrition, movement, etc.). OWL-H also provides subjects a facilitated community blog, private journal, peer support, and an extensive resource library. It will be tested by 26 patients with hypertension, to refine the platform based on patient feedback and outcomes.
Study NCT04987567 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ANTIOXIDANT DHA TRIGLYCERIDE (TRIDOCOSAHEXAENOINE-AOX®)
Description: Pearls of DHA (BrudyNen)
Study NCT04987567 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO (OLIVE OIL)
Description: Pearls manufactured to mimic DHA (BrudyNen).
Study NCT02091583 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Butter, sunflower and safflower oil
Study NCT02091583 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High Oleic Canola Oil and DHA (HOCO-DHA)
Study NCT02091583 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Barley beta-glucan
Study NCT02091583 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HOCO-DHA and Barley beta-glucan
Study NCT03210103 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation
Description: Standard of Care: Radiation +/- Chemotherapy
Study NCT03210103 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transoral Surgery (TOS) + Neck Dissection
Description: Transoral Surgery (TOS) + Neck Dissection (plus radiation, if required)
Study NCT02777229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg
Description: 1 tablet once a day
Study NCT02777229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate 300 mg / lamivudine 300 mg
Description: Fixed dose combination, 1 tablet once a day
Study NCT02777229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil fumarate 300 mg / lamivudine 300 mg
Description: Fixed dose combination, 1 tablet once a day
Study NCT02777229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz 400 mg
Description: 1 tablets once a day
Study NCT02111460 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Loco-regional Radiotherapy
Description: with or without Loco-regional Radiotherapy
Study NCT02111460 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Loco-regional Radiotherapy
Description: with or without Loco-regional Radiotherapy
Study NCT04263350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir/Cobicistat
Description: Specified Dose on Specified Days
Study NCT04263350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reyataz Atazanavir
Description: Specified Dose on Specified Days
Study NCT04263350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: Specified Dose on Specified Days
Study NCT00706550 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: (PV) 23-valent pneumococcal polysaccharide vaccine
Description: Currently commercially available pneumococcal polysaccharide vaccine
Study NCT00706550 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Placebo
Description: Placebo
Study NCT01573078 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire consisting of the following validated surveys: Rome II criteria - Scale of Body Connection (SBC), Private Body Consciousness Sub-Scale (PBCS), Body Vigilance Scale (BVS), Emotional Processing Scale (EPS25)
Study NCT02807051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Single 400-mg dose (four 100-mg capsules) administered in the morning on Days 1 and 12
Study NCT02807051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Twice-daily, 500-mg dose (one 500-mg tablet) administered every 8 to 12 hours on Day 8 through the morning of Day 12
Study NCT02807051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib and Clarithromycin
Description: On Day 12, a single oral 400-mg dose of pacritinib was co-administered with the final 500-mg dose of clarithromycin
Study NCT01294488 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-Child Interaction Therapy
Description: Therapists receive training in Parent-Child Interaction Therapy (PCIT) and receive supervision in their implementation of PCIT skills via phone consultation and polycommunication technology, each for 6 months.
Study NCT03838198 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: MI-Enhanced Safety Plan at Hospitalization (1st Component)
Description: The MI-enhanced safety plan intervention component is delivered during hospitalization and includes an individual and family meetings. The goal of the individual meeting with the adolescent is to develop an individualized safety plan for use during a suicidal crisis. This best practices approach of safety planning is augmented with Motivational Interviewing (MI) as a core strategy to explicitly elicit adolescents' motivation and commitment to behavior change (i.e. use safety plan; adaptive coping), address barriers or ambivalence, and strengthen self-efficacy. The focus of the family meeting, which is similarly guided by MI, is to prepare parents/guardians, with input from the adolescent, for how they may support the adolescent in implementing the individualized safety plan after discharge and on strengthening parents' commitment and self-efficacy.
Study NCT03838198 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: MI-Enhanced Text Boosters (2nd Component)
Description: For participants randomized to receive text boosters, booster text messages will be sent daily for 4 weeks. The messages will be tailored to encourage use of individualized coping strategies identified as part of safety planning at hospitalization and will include additional adaptive coping tools and resources. The text message content and tone will be consistent with principles of MI.
Study NCT03838198 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: MI-Enhanced Booster Call (3rd Component)
Description: The focus of the post-discharge booster phone call with adolescent and with parent, each conducted separately, will be to to further adjust the safety plan to better meet post-discharge needs, to further enhance adolescents' motivation and commitment to use coping strategies, and to further support adolescents' and parents' self-efficacy to manage suicidal crises.
Study NCT00992979 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Massage
Description: Massage therapists with at least 5 years experience will perform the massages. On each of three consecutive days, participants (while fully clothed and in a seated position) will receive a 20-minute back, shoulder, neck and head massage. Subjects will be treated with conventional light pressure Swedish massage techniques which consisted of continuous systematic strokes including kneading and stretching to loosen and rehabilitate the soft tissues of the body and to provide general relaxation. The manual techniques include: effleurage , soothing petrissage , repetitive stroking, rocking , squeezing and mild joint mobilization. As is standard practice in massage therapy delivery, room lights will be dimmed and soft, soothing music played to enhance relaxation during therapy.
Study NCT00992979 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Control
Description: On each of three consecutive evenings, subjects in this group will participate in a 20 minute relaxation session. This session will be delivered in the same location and with the same lighting and music as with the therapeutic massage group. Each participant will be asked to choose a comfortable position in a chair and a massage therapist will sit quietly in the room approximately 4 feet behind the participant.
Study NCT03881384 — intervention group
Intervention type: OTHER
Intervention: ctDNA level during neoadjuant chemotherapy
Description: Draw blood from each enrolled patient every time before chemotherapy and measure the ctDNA level in plasma.
Study NCT04374643 — intervention group
Intervention type: OTHER
Intervention: Slef questionnaires fulfilment
Description: Questionnaires to assess the psychological impact of confinement and its evolution over 6 months
Study NCT04184492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP-40081
Description: biphasic insulin aspart 30 in doses 0.4 IU/kg
Study NCT04184492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NovoMix® 30 Penfill®
Description: biphasic insulin aspart 30 in doses 0.4 IU/kg
Study NCT04559204 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IIV4 and PPV23
Description: imultaneously immunization of 23-valent pneumococcal polysaccharide vaccine (PPV23) and quadrivalent inactivated influenza vaccine (IIV4)
Study NCT04559204 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IIV4
Description: administrated with IIV4 only
Study NCT04559204 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPV23
Description: administrated with PPV23 only
Study NCT00117507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Study NCT02375724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium Bromide
Description: Inhaled Aclidinium 400 μg twice per day by Eklira Genuair Inhaler
Study NCT02375724 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled dose-matched placebo, twice per day by Eklira Genuair Inhaler
Study NCT05087355 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PCR or antigen test for Covid 19 or Inluenza
Description: PCR or antigen test for Covid 19 or Inluenza
Study NCT01290055 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow fever vaccine
Description: The yellow fever vaccine (YFV-17D) manufactured by Sanofi Pasteur as a one-dose vial will be purchased from the manufacturer. Vaccine will be stored at the Emory Investigational Drug Service (IDS) between 2 to 8 degrees Celsius as per the manufacturer's instructions. It will be transported to the Hope Clinic per the Standard Operating Procedures.
Study NCT01290055 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deuterium (70% enriched 2H2O) labeled water
Description: 70% enriched 2H2O will be obtained from Cambridge Isotope Laboratories (Andover, MA) in sterile 1 Liter containers. An Emory Investigational Drug Service (IDS) pharmacist will prepare sterile 50 milliliter aliquots with a tamper seal which will be transported to the Hope Clinic at room temperature.
Study NCT05183113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Intermittent Hypoxia
Description: Participants will wear a non-rebreathing face mask and alternate between breathing 9% O2 gas mixture for up to 1 minute, or until the target SpO2 of 85 percent is reached, and normal room air (21 percent O2) until 2 minutes are complete. This cycle will be repeated 15 times, resulting in a 30-minute protocol.
Study NCT01134835 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks
Study NCT01134835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP Pioglitozone
Description: Pioglitazone 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks and placebo 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks.
Study NCT04457466 — intervention group
Intervention type: DRUG
Intervention: Nerve Growth Factor
Description: Induction of experimental muscle soreness using intramuscular injections of Nerve Growth Factor.
Study NCT04450511 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic stimulation -Armchair type (MS)
Description: MS was applied two days a week, 20 minutes a day, a total of 12 sessions for 6 weeks.
Study NCT04450511 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bladder Training (BT)
Description: Bladder Training (BT)
Study NCT04450511 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bladder Training (BT)
Description: Bladder Training (BT)
Study NCT02819076 — intervention group
Intervention type: OTHER
Intervention: pain scale
Study NCT01365585 — intervention group
Intervention type: DRUG
Intervention: sildenafil citrate
Description: Sildenafil citrate, 20mg oral tablets, taken at least three times daily
Study NCT00697450 — intervention group
Intervention type: DRUG
Intervention: insulin detemir
Description: Start dose, frequency of dosing, dose titration to be prescribed by the physician as a result of a normal clinical evaluation
Study NCT02150525 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acid
Description: Given PO (by mouth) daily